Company Culture

Quote
anonymous said:
O M G ;
it is so wired , in Germany no, no raised sales, in portugal no raised in sales,... only in spain raised stock by wholsales pharmacy, in italy raised stock in wholesale pharmacy , no raised sales in UK,
no raised sales in USA , so wtf is the record growth
I hope some day the SEC would have a deeper look in these bc mafia clan.
Click to expand...

The Securities and Exchange Commission has awarded more than $250 million to whistleblowers since the inception of the agency’s whistleblower program in 2011.

https://www.sec.gov/whistleblower
 






Alimera Sciences Quarterly Cash on Hand
(Millions of US $)

2018-06-30 $16.7
2018-03-31 $20
2017-12-31 $24
2017-09-30 $26
2017-06-30 $27
2017-03-31 $27
2016-12-31 $31
2016-09-30 $34
2016-06-30 $17
2016-03-31 $24
2015-12-31 $31
2015-09-30 $39
2015-06-30 $48
2015-03-31 $61
2014-12-31 $77
 
























Security ALIM / Alimera Sciences, Inc.
Form Type 8-K
File Date 2018-08-01

Given that our stock price is currently trading close to $1.00 per share, however, it is possible that we may again fail to comply with Nasdaq’s minimum bid requirement. If that were to occur and we were to fail to regain compliance with this continuing listing requirement, our shares could be delisted from the Nasdaq Global Market, which could materially reduce the liquidity of our common stock and have an adverse effect on its market price. A delisting would likely make it more difficult for us to obtain financing through the sale of our equity. Any such sale of equity would likely be more dilutive to our current shareholders than would be the case if our shares were listed.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALIMERA SCIENCES, INC.
Dated: August 1, 2018
By:
/s/ RICHARD S. EISWIRTH, JR.
Name:
Richard S. Eiswirth, Jr.
Title:
President and
Chief Financial Officer
 






QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018

Meaningful factors that could cause actual results to differ include:
  • uncertainty regarding our ability to achieve profitability and positive cash flow through the commercialization of ILUVIEN® in the U.S., the European Economic Area (EEA) and other regions of the world where we sell ILUVIEN;
  • dependence on third-party manufacturers to manufacture ILUVIEN or any future products or product candidates in sufficient quantities and quality;
  • our ability to successfully obtain the indication for non-infectious posterior uveitis in the EU;
  • the possibility that we may again fail to comply with the continuing listing standards of the Nasdaq Global Market because the closing bid price of the our common stock on the Nasdaq Global Market is below $1.00 for 30 consecutive business days;
  • our ability to operate our business in compliance with the covenants and restrictions in our credit facility;
  • our possible need to raise additional financing.
 






Cantor Fitzgerald alleges that our agreement in October 2016 with Hercules Capital, Inc. (Hercules) to restructure and amend our then existing $35 million debt facility with Hercules and to secure an additional $10 million in debt financing requires the payment to Cantor Fitzgerald of an advisory fee of 2% of $45 million, or $900,000, plus expenses of $24,890. Cantor Fitzgerald seeks compensatory and punitive damages, pre- and post-judgment interest, plus attorneys’ fees and costs.
 












so this is RI alimera stroy for the SEC , today Alimera did fire some employee in EEA to reduct the costs.
aaand they are do not go the nice and soft way.
they sacrifice a pawn, when they fire some sales emloyee with some profit. And held up to the bunch of
some high paid dumpa_ses.

And howe do they want to raised up sales. in EEA comes in serval month some new medication for uveitis
with this there is no need for iluvien treatmet . And there is still the problm with the dull application.
more physician are frustrated and didn´t want to use these dull , dump crap.

best wishes for the last worker there , they needed many many luck
 


















40147141956_f3aaf3_o.jpg

17 days ago

Q2; Revenue up $0.6 mill and operating expenses increased with 1.9 mill. Only The big failure can make a positive history out of that. Now he says that the positive revenue in Q2 2017 was due to inventory fluctuations.... He did not say anything about that in his Q2/2017 reporting. Then he just said that revenue was increasing. And How can the deputy of the big failure say that he expect that Alimera has enough cash to run the company until they have achieved break even. Their losses becomes bigger quarter by quarter ( 4 million dollars this quarter - 2.8 million dollars last year) and they have only 16 million dollars left. Is he stupid or can't he read the numbers and the writing on the wall?
 












38837666923_d27c97_o.jpg

4 months ago

STOP TAKING MONEY DAN MYERS & Co!!! You have proven you CANNOT make a profit or at least break even but you can increase your "sales meetings" year over year. Since you & your commands are currently in Hawaii today (the second Hawaiian trip this year), do the Shareholders a favor, don't come back!!! 19 ophthalmic meetings in the first 3 months of 2018...personal expenses up $600k...this isn't a joke it's a crime!!!

https://finance.yahoo.com/quote/ALIM/community?p=ALIM
 






























Lenweaver v. Alimera Sciences, Inc.

Order by Judge Edward M. Chen granting 31 Stipulation to Continue Court Ordered Mediation Completion Date. Mediation completion date of 9/27/2018 is vacated. Mediation shall be completed by 10/31/2018. Plaintiff's deposition will take place on 9/28/2018.
 






Top Bottom
Back
Quote